Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health, Inc. Chief Commercial Officer Chris Freeman reported conversion of 7,416 restricted stock units into common stock on October 1, 2026, and 3,143 common shares retained by the Company for tax withholding. The retained shares met tax obligations associated with vesting an installment of restricted stock units.
Guardant Health, Inc. Chief Technology Officer Darya Chudova reported conversion of 8,033 restricted stock units into common stock on October 1, 2026. On the same date, the company retained 4,320 shares to meet the award-holder’s tax withholding obligations, at a reported price of $174.75 per share. The filing states the amount retained did not exceed the tax liability.
Guardant Health, Inc. Chief Financial Officer Michael Brian Bell reported conversion of three restricted stock unit awards into 2,085, 3,324 and 1,871 shares of common stock on October 1, 2026. Guardant Health retained 3,914 common shares to meet the award-holder’s tax-withholding obligation, at a reported $174.75 per share; the related footnote says the amount retained did not exceed the tax liability.
Guardant Health, Inc. co-CEO AmirAli Talasaz reported restricted stock unit conversions and common-share acquisitions by the Talasaz and Eskandari 2017 Family Trust. On September 30, 2026, 2,817 RSUs converted into 2,817 common shares held by the trust, and 1,428 shares were withheld for tax liability. On October 1, 2026, 23,997 and 9,716 RSUs converted into corresponding common shares held by the trust; 17,087 shares were withheld for tax liability.
Guardant Health, Inc. Co-Chief Executive Officer and director Helmy Eltoukhy reported restricted stock unit conversions resulting in 36,530 common shares held indirectly through the Helmy A. Eltoukhy Revocable Trust. The company retained 18,515 shares to meet tax-withholding obligations: 1,428 shares at $178.36 per share on September 30, 2026, and 17,087 shares at $174.75 per share on October 1, 2026. No Rule 10b5-1 plan is reported.
Guardant Health, Inc. (GH) director Roberto Mignone reported the vesting and conversion of 264 Restricted Stock Units into 264 shares of Common Stock on September 21, 2026, at a stated price of $0.00 per share. After these events, he holds 10,274 shares of Common Stock and 6,600 Restricted Stock Units, all held directly. The Restricted Stock Units were granted on November 8, 2024 and vest over four years, with 25% vesting on October 21, 2025 and the remaining 75% vesting monthly over the following three years.
Guardant Health, Inc. (GH) director Manuel Hidalgo Medina reported the vesting and conversion of 232 Restricted Stock Units232 shares of Common Stock5,020 shares of Common Stock
The RSUs relate to an award granted on July 17, 2024 that vests over four years, with 25% vesting on July 17, 2025 and the remaining 75% vesting monthly over the following three years. No Rule 10b5-1 trading plan is reported for these transactions.
Guardant Health, Inc. (GH) reported that Chief Technology Officer Darya Chudova sold 7,738 shares of common stock on September 15, 2026 in a sale characterized as an open market or private transaction at $178.00 per share. After this transaction, she directly holds 70,635 shares of Guardant Health common stock. No Rule 10b5-1 trading plan is reported for this sale.
Guardant Health, Inc. (GH) director Steve E. Krognes reported selling a total of 6,674 shares of common stock on September 16, 2026 in four open-market or private transactions. Each sale was reported at a weighted average price with price ranges from $173.98 to $177.945 per share, and no Rule 10b5-1 trading plan is indicated.
Guardant Health, Inc. (GH) director Alex M. Azar II reported selling 826 shares of common stock on September 16, 2026 in a sale described as occurring in the open market or a private transaction at a reported price of $175.00 per share. The transaction was reported as made under a Rule 10b5-1 trading plan, and following the sale he held 825 shares of Guardant Health common stock directly.